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SYNONYMS 
Major depression; endogenous depression; unipolar depression; melancholia 
 
 
DEFINITION 
Major depression is the most severe category of depression and is marked by a combination of 
symptoms that occur together and last for at least two weeks without significant improvement.  
 
Symptoms from at least five of the following categories must be present for a major 
depression, although even a few of the symptom clusters are indicators of a depression, but 
perhaps not a major depression: 
 
• Persistent depressed, sad, anxious, or empty mood 
• Feeling worthless, helpless, or experiencing excessive or inappropriate guilt 
• Hopeless about the future, excessive pessimistic feelings 
• Loss of interest and pleasure in usual activities 
• Decreased energy and chronic fatigue 
• Loss of memory, difficulty making decisions or concentrating 
• Irritability or restlessness or agitation 
• Sleep disturbances, either difficulty sleeping, or sleeping too much 
• Loss of appetite and interest in food, or overeating, with weight gain 
• Recurring thoughts of death, or suicidal thoughts or actions  
 
 
CHARACTERISTICS 
 
History/Background 
 
Descriptions of what is today known as depression or mood disorders appear in many ancient 
documents. About 400 B.C. Hippocrates used the terms mania and melancholia to describe 
mental disturbances. Around 30 A.D., in his work “De re medicina” the Roman physician 
Celsus described melancholia (from the Greek “melan” meaning “black” and “chole” 
meaning “bile”) as a depression caused by black bile. 
 
In 1899, the German psychiatrist Emil Kraepelin, building on the ideas and theories of earlier 
French and German psychiatrists, described manic-depressive psychosis; according to 
Kraepelin,  a dementing or deteriorating course in manic-depressive psychosis differentiated it 
from dementia praecox (as schizophrenia was then called). Kraepelin also described a 
depression that later came to be known as involutional melancholia as a form of depression 
beginning in late adulthood.  
 
Epidemiological studies have shown that depressive disorders are more common and have a 
less favourable course than previously assumed. Concepts of diagnosis have also changed 
over time. The entity of endogenous depression, part of Kraepelin’s systematic, triadic 
nosology (1913), was abandoned in favour of depressive episodes, as defined in ICD-10 
(WHO 1992), and major depression as defined in DSM-IV (APA 1994). These became the 
new major diagnostic categories for depressive disorders. The heterogeneity of the depressive 
syndrome results in a continuous demand for new attempts at classification. When the current 
DSM-IV and ICD-10 systems for the classification of depressive disorders are considered 
from the controversial historical perspective, it becomes clear that the distinction between 
unipolar and bipolar disorders has prevailed and that classification on the sub-syndrome level 
has been taken up again, albeit in a somewhat modified form. The main change occurring in 
the transition from ICD-9 to ICD-10 was the abandonment of the distinction between 
endogenous and neurotic forms of depression: this distinction was considered to be too 
etiologically oriented, and could not be adequately validated on an empirical basis.  
 
 
Diagnostic considerations 
 
There is no general agreement about the best method of classifying depressive disorders. 
Three broad approaches have been made: first to base classification on etiology, second on 
symptoms and third on the course of the disorder.  
 
Both ICD-10 and DSM-IV classify depressive episodes on the basis of severity and whether 
or not psychotic features are present. It is also possible to specify whether a depressive 
episode has melancholic (DSM-IV) or somatic (ICD-10) features. In DSM-IV, an episode of 
major depression with the appropriate clinical symptomatology can be specified as atypical 
depression. In ICD-10 atypical depression is classified separately under “other depressive 
episodes”. Both ICD-10 and DSM-IV allow the diagnosis of recurrent brief depression. 
Nowadays it is argued that the phenomenologically-based concept of “major depression” has 
led to sterility in depression research and clinical practice, and that there is a need for a 
paradigm shift in modelling and classifying the depressive disorders [1]. 
 
 
Epidemiology 
 
Major depressive disorder is a common disorder, with a lifetime prevalence of about 15% and 
perhaps as high as 25% for women. The incidence of major depressive disorder is 10% in 
primary care patients and 15% in medical inpatients. 
 
An almost universal observation, independent of country or culture, is that major depressive 
disorder is twice as prevalent in women than in men. Possible reasons for this are hormonal 
differences, the effects of childbirth, different psychosocial stressors for women than for men 
and behavioural models of learned helplessness.  
 
The gender differences have been found in community samples and can thus not be accounted 
for by the fact that women are more likely to seek help than men. Race, education, income 
and marital status do not influence prevalence rates for major depressive disorder. Recent 
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epidemiological data clearly indicate that the age of onset of major depressive disorder has 
decreased in recent years (the “birth cohort” effect) in many Western cultures [2].  
 
The lifetime psychiatric co-morbidity rate for major depressive disorder can be as high as 
43% [3], i.e. up to 43% of patients with major depressive disorder have a history of one or 
more non-mood psychiatric disorder. The one-month point prevalence for concurrent in 
contrast to lifetime psychiatric co-morbidity is 8%.  
 
There is strong empirical evidence suggesting that psychosocial events or stressors may play a 
significant role in precipitating the first or second episode of major depressive disorder, but 
this becomes less important for the onset of subsequent episodes [4]. This means that for the 
recurrent forms of major depressive disorder, new episodes are less likely to involve a specific 
precipitant as the disorder becomes more firmly established.  
 
 
Course and outcome 
 
Periods of significantly increased risk for the onset of the illness include late adolescence and 
early adulthood, with a progressively increasing incidence up to the age of 45. The age of 30 
is usually considered the typical age of onset, although more recent investigations have 
implied that the average age of onset is considerably earlier [5]. Contrary to the traditional 
clinical conception that the highest rates for depression are found in older persons, more 
recent studies have found the highest rates in younger age-groups [6]. An increasing number 
of young patients develop depression at earlier and earlier ages. It seems likely that the 
increased risk of depression in younger people is environmentally mediated, but the factors 
involved are unknown [7].  
 
Major depression is 2.5 times more common in separated people living alone [5].  
 
People who have been unemployed for at least six months of the five years preceding 
diagnosis are three times more likely to develop an episode of major depression. 
 
Critical life events with respect to inter-personal relationships, particularly the death of a close 
friend of relative, and physical illness combined with poor social resources (e.g. inadequate 
social support) and personal resources (e.g. dysfunctional coping behaviour) are found 
primarily in depressive cases [8]. An earlier onset of illness, a slower rather than an acute 
onset, the presence of dysthymia, the presence of chronic physical illness and above all the 
presence of a chronic anxiety disorder all significantly increase the risk of chronic depression.  
 
The duration of the episodes varies, but several prospective studies have shown that affective 
disorders remit completely much more often than anxiety disorders (ratio: 32% - 46%).  
 
The remission rate (defined as five years without relapse) is 42% for unipolar depressive 
illnesses.  
 
For those who experience a first depressive episode, the risk of recurrence is 80 – 90%. About 
50% of patients with major depressive disorder become chronic cases: more than 20 – 30% do 
not respond to antidepressant medication, with up to 60% of primary care patients remaining 
depressed after 12 months and 20% of clinic patients remaining depressed for over two years 
despite pharmacological treatment. Further, one third of those initially responding to 
medication relapse within one year, with up to 75% relapsing within five years. Chronic 
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depression leads to psychosocial deficits, which place a tremendous burden on both patients 
and society. It is not only associated with various somatic illnesses, but also entails massive 
economic costs. According to the WHO, it is predicted that depression will become the major 
burden on mental health services by the year 2020.  
 
The risk of suicide has been estimated at 15% and is thus considerably higher than in the 
normal population. Co-morbid depressive episodes last significantly longer than non-co-
morbid depression and have a considerably higher rate of relapse.  
 
 
Etiology 
 
Genetic causes 
 
Most family studies have shown that parents, siblings and children of severely depressed 
patients have a morbid risk of about 20% for mood disorders, as compared with about 7% for 
the relatives of controls. The concordance rates for manic depressive disorder were 69% for 
monozygotic twins reared together, 67% for monozygotic twins reared apart, and 13% for 
dizygotic twins.  
 
 
Neurodevelopment factors 
 
It has been proposed that stress-induced changes in the hippocampus may be central to the 
development of depression in genetically vulnerable individuals. New evidence implicates the 
pre-frontal cortex (PFC) in addition to the hippocampus as a site of neuropathology in 
depression. The PFC may be involved in stress-mediated neurotoxicity as stress alters PFC 
functions and glucocorticoid receptors, the PFC is directly inter-connected with the 
hippocampus, and metabolic alterations can be seen in the PFC in depressed patients. Post-
mortem studies in major depression provide preliminary evidence for specific neuronal and 
gliohistopathology in mood disorders. Three patters of morphometric cellular changes are 
noted: cell loss (subgenual PFC), cell atrophy (dorsolateral PFC and orbitofrontal cortex) and 
increased numbers of cells (hypothalamus, dorsal raphe nucleus, cf. [9]).  
 
 
Neurotrophic factors 
 
Several neurotrophic factors (such as nerve growth factor, NGF, brain-derived neurotrophic 
factor, BDNF, and glio-derived neurotrophic factor, GDNP), as well as cytokines and insulin-
like growth factor-1 (IGF-1) increase cell survival. The cAMP response element-binding 
protein (CREB) is a critical integrator of neuroplasticity that is responsive in a brain region-
specific manner to a variety of environmental and pharmacological stimuli, including widely 
prescribed antidepressant medications. CREB is an ubiquitous key-element of intracellular 
signal transduction cascades that may contribute to symptoms of depression. The increase in 
CREB-phosphorylation might be a molecular state marker for the response to antidepressant 
treatment. 
 
There is emerging evidence -  primarily from post-mortem studies – supporting the role of 
abnormalities in neurotrophic signalling pathways in depression. Recent studies suggest that 
stress-induced atrophy and loss of hippocampal neurons may contribute to the 
pathophysiology of depression. At the cellular level, evidence has emerged indicating 
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neuronal atrophy and cell loss in response to stress and in depression. At the molecular level, 
it has been suggested that these cellular deficiencies, mostly detected in the hippocampus, 
result from decreased expression of BDNF associated with elevation of glucocorticoids.  
 
 
Serotonergic markers 
 
Imipramine binding to blood platelets is generally decreased in depression, as indicated by 
decreased maximal binding capacity. Similarly, 5-HT-uptake in blood platelets is decreased. 
These findings correspond to a decreased maximal binding capacity of imipramine to brain 
tissue. Imipramine binding to platelets is a robust biological marker for depression.  
 
 
5-HT-receptors 
 
Due to the efficacy of serotonergically acting drugs in major depression, some 5-HT-receptors 
have been extensively studied in major depression. Almost all the studies point to a decreased 
or unchanged expression of the 5-HT-1A-receptor. A trend towards decreased 5-HT-1A- 
receptor expression appears to be a robust finding in major depression. 
 
 
Biochemical markers 
 
Several studies have investigated lipids as biological markers for depression. 
Hypocholesterolemia has been associated with depression, suicide and affective disorders. 
Low or lowered cholesterol may be associated with increases of suicides and accidents. 
Cholesterol levels have been identified as a blood marker for depression and anxiety in a 
normal population in a primary care setting. A hypertriglyceridemia-driven metabolite cause 
of depression has also been demonstrated in controlled clinical trials, showing that 
trigylceride lowering alleviates the symptoms of depression. Recent evidence has suggested 
an important role for lipids in the etiology and treatment of depression. There is empirical 
evidence for the hypothesis that unipolar depression may be associated with abnormalities in 
lipid-associated signalling systems. 
 
 
Vitamins: folic acid 
 
Several cross-sectional studies have focussed on the low blood folate levels in depression 
patients. In a large Finnish study, depressed patients in the general population with energy-
adjusted folate intake below the median had a higher risk of being given the discharge 
diagnosis of depression during the follow-up period than those with a folate intake above the 
median. A low dietary intake of folate may be a rsik factor for severe depression.  
 
 
Vitamins B6 and B12 
 
A group of Danish investigators have suggested that a low level of vitamin B6 is associated 
with symptoms of depression. A low plasma level of the vitamin B6 derivate, puridoxal 
phosphate (POP), was significantly associated with the depression score. Higher vitamin B12 
levels were significantly associated with better outcome. Vitamin B12 level may thus be 
positively associated with the probability of recovery from major depression.  
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G-proteins 
 
Abnormal signal transduction pathways have been implicated in the pathogenesis of major 
depression. G-proteins are key elements of these pathways in the regulation of cellular 
responses by transmission of signals from receptors to effector proteins. Several studies have 
reported altered levels and activities of G-protein subunits in depressive patients. 
 
Although it is well established that depression is major risk factor for the development of 
coronary artery disease and that cerebro-vascular disease can be a major contributing factor 
for the development of depression, the information interplay between the central nervous and 
system and cardio-vascular disease is still limited. In an investigation of the G-protein beta-3-
subunit C825T polymorphism and the angiotensine-1 converting enzyme (ACE) ID 
polymorphism, analysis of both genes showed that the combined actions of ACE and C825T 
genotypes accumulate in carriers of the ACE-D allele and C825T-TT nomozygates with 
IC/DD-TT carriers showing a more than fivefold increase in risk for major depression. Thus, 
the study reports that the same allelic combination of two genes that have been shown to 
increase the risk for myocardial infarction increase the vulnerability for depressive disorder. 
This finding strengthens the evidence for the involvement of G-protein-couple signal 
transduction in the pathogenesis of affective disorders. 
 
 
Hypothalamic pituitary-adrenal axis 
 
The HPA axis stimulating properties of higher ACE and consecutively higher angiotensine 
and lower substance peak concentrations may be crucial factors for the HPA system 
hyperactivity during major depressive episodes. 
 
The corticotropin-releasing hormone binding protein gene is likely to be involved in the 
genetic vulnerability for major depression. 
 
 
Neural imaging markers 
 
Positron emission tomography (PET) imaging studies have revealed multiple abnormalities in 
regional cerebral blood flow (CBF) and glucose metabolism in limbic structures and the 
prefrontal cortex (PFC) in mood disorders. In unmedicated subjects with major depression, 
regional CBF and metabolism are consistently increased in the amygdala, orbital cortex and 
medial thalamus, and decreased in the dorsomedial/dorsal anterolateral PFC and anterior 
cingulate cortex ventral to the genu of the corpus callosum (subgenual PFC), compared with 
healthy controls [10]. These abnormalities implicate limbic-thalamic-cortical and limbic-
cortico-striato-pallidal-thalamic circuits involving the amygdala, orbital and medial PFC, and 
anatomically related parts of the striatum and thalamus in the pathophysiology of major 
depression. These circuits have also been implicated more generally in emotional behaviour 
by the results of electrophysiological, lesion analysis and brain-mapping studies in humans 
and experimental animals. Structural imaging studies have demonstrated reduced grey-matter 
volumes in areas of the orbital and medial PFC, ventral striatum and hippocampus, and 
enlargement of the third ventricle. It is not known whether these deficits constitute 
developmental abnormalities that may confer vulnerability to abnormal mood episodes, 
compensatory changes to other pathogenic processes, or the sequelae of recurrent affective 
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episodes per se [9]. Taken together with other pre-clinical data regarding these structures’ 
specific roles in emotional processing, the neuro-imaging and neuropathological 
abnormalities in major depression suggest that the illness is associated with the activation of 
regions that putatively mediate emotional and stress responses, whereas areas that appear to 
inhibit emotional expression (such as posterior orbital cortex) contain histological 
abnormalities that may interfere with the modulation of emotional or stress responses. 
 
 
Cognitive deficits in major depression 
 
There is growing evidence that several cognitive domains are significantly impaired in 
patients with major depression, including attention, memory and executive functioning. 
Patients with major depression manifest significant impairment in their ability to maintain 
attention in tasks requiring strenuous mental operations, i.e. tasks requiring selective and 
sustained attention or implying a large resource-allocation capacity.  
 
Patients with major depression also have widespread executive dysfunction, including 
working memory, set-shifting and inhibition processes, even during the euthymic state.  
 
It has been suggested that cognitive deficits in major depression may depend on age, severity 
of illness and psychotic or melancholic features. Cognitive deficits in depression may be 
associated with both trait and state factors and raise questions regarding the long-term 
cognitive functioning in patients with major depression. These deficits may be explained by 
structural or functional changes associated with the severity of illness, ageing effects or a 
possible cumulative pathologic effect of depression on brain structure and function across 
recurrent episodes of illness [9]. 
 
In summary, none of the biological and neuropsychological markers (see Fig. 1) have been 
shown to be sufficiently specific to allow inclusion in diagnostic manuals of major 
depression. 
 
Fig. 1 
Biological markers of depression 
 
 
Sleep abnormalities 
 
Problems sleeping – initial and terminal insomnia, multiple awakenings, hypersomnia – are 
common and classic symptoms of depression. The sleep electroencephalograms (EEGs) of 
many depressed persons show abnormalities. Common abnormalities are delayed sleep onset, 
shortened rapid eye movement (REM) latency (the time between falling asleep and the first 
REM period), a longer first REM period and abnormal delta sleep. 
 
 
Circadian rhythms 
 
The abnormalities in sleep architecture in depression and the transient clinical improvement 
associated with sleep deprivation have led to theories that depression reflects the abnormal 
regulation of circadian rhythms. Experimental studies with animals indicate that many of the 
standard antidepressant treatments are effective in changing the setting of internal biological 
clocks (endogenous zeitgebers).  
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Psychosocial factors 
 
Life events and environmental stress 
 
Stressful life events precede more often first rather than subsequent episodes of major 
depression. According to Post [4], the stress accompanying the first episode results in long-
lasting changes in the brain’s biology. These long-lasting changes may alter the functional 
states of various neurotransmitter and intra-neuronal signalling systems, and may even 
include the loss of neurons and an excessive reduction in synaptic contacts. This greatly 
increases the risk of subsequent episodes of a mood disorder, even without an external 
stressor.  
 
The most compelling data indicate that the life event most often associated with the 
development of depression is losing a parent before the age of 11. The environmental stressor 
most often associated with the onset of an episode of depression is the loss of a spouse. 
Another risk factor is unemployment: persons out of work are three more times more likely to 
report symptoms of an episode of major depression than those working.  
 
 
Personality factors 
 
All humans, regardless of their personality pattern, can and do become depressed under 
appropriate circumstances. Persons with certain personality disorders – obsessive-compulsive, 
histrionic and borderline – may be at greater risk for depression than persons with antisocial 
or paranoid personality disorder. The latter can use projection and other externalising defence 
mechanisms to protect themselves from their inner rage. Patients with dysthymic and 
cyclothymic disorder are at risk of developing major depression or bipolar I disorder later. 
 
Stressors experienced by the patient as reflecting more negatively on his/her self-esteem are 
more likely to result in depression. What may seem to be a relatively mild stressor to outsiders 
may be devastating for the patient because of particular idiosyncratic meanings attached to the 
event.  
 
 
Pharmacotherapy 
 
Since the introduction of the first tricyclic antidepressant, imipramine, in 1957, many new 
types of antidepressants have been developed. The classes of substances currently available 
differ little in their antidepressant effect; there is no convincing evidence that one particular 
class of antidepressant is more effective or has a more rapid onset of effect than the others. 
The newer antidepressants of the 1980s and 1990s generally have less serious side effects 
than the “classic” substance groups of the tricyclic agents and the irreversible monoamine 
oxydase (MAO) inhibitors. Approximately 30 - 40% of  both in- and out-patients fail to 
respond adequately to an initial 4 – 6 week treatment with an antidepressant. As many as 10 – 
15% of patients fail to improve sufficiently, even after several different treatment attempts. 12 
– 15% of depressive patients are not yet asymptomatic two years after onset of the illness. The 
lack of success of antidepressant therapy is often due not to the illness itself, but to sub-
optimal treatment. If resistance to therapy remains intractable despite attempts at treatment 
optimisation, the use of augmentative or combination therapy should be considered. Among 
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augmentative therapies, the addition of lithium to traditional antidepressants, has been found 
useful. Combination therapy with various antidepressants has been tried with varying success, 
as has so-called pindolol augmentation, a combination of the beta-blocker pindolol with a 
serotonin-reuptake inhibitor (SSRI). The combination of a neuroleptic with an antidepressant 
has proven useful in the treatment of depression with psychotic features. 
 
 
Psychotherapy 
 
The majority of patients with an episode of major depressive disorder respond to the first or 
second attempted treatment. In patients with mild or moderately severe episodes, treatment 
with antidepressant drugs and brief psychotherapies are adequate and equally effective. In 
those with severe episodes, antidepressant medication alone or a combination of medication 
and psychotherapy is recommended. The treatment of chronic depression and in particular of 
patients failing to respond to adequate drug treatment (approximately 20%) is more 
problematic. In addition, these patients have marked impairment in psychosocial functioning, 
incomplete remission even after two years and very high rates of use of healthcare resources. 
Furthermore, even if there is a partial remission, there remains a high risk of relapse (up to 
80%). 
 
Many studies indicate that a combination of psychotherapy (cognitive behavioural 
psychotherapy, psychodynamic psychotherapy, interpersonal psychotherapy) and 
pharmacotherapy is the most effective treatment for major depressive disorder. Some data 
suggest another view: either pharmacotherapy or psychotherapy alone is effective, at least in 
patients with mild major depressive episodes.  
 
Three types of short-term psychotherapy (cognitive therapy, interpersonal therapy and 
psychodynamic psychotherapy) have been studied to determine their efficacy in the treatment 
of major depressive disorder.  
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